hn.today

Why demand for the shingles vaccine is soaring

theguardian.com6 points1 comments
Screenshot of Why demand for the shingles vaccine is soaring

Demand for the shingles vaccine has surged as many people are seeking not only protection from painful shingles but also a possible reduction in dementia risk. High-street pharmacies report bookings up sharply (Boots bookings more than doubled year-on-year; Superdrug up 41%), and under-65s typically pay about £450 for the two-dose course while some receive it free on the NHS. The trend follows several large observational studies: a natural experiment in Wales around eligibility for the live-attenuated Zostavax found an 8.5% lower dementia rate in vaccine-eligible women over seven years, implying nearly a 20% reduction among those vaccinated; an Oxford analysis of more than 200,000 US records comparing Shingrix (a non-live, adjuvanted vaccine) with Zostavax reported a 17% lower dementia incidence with Shingrix, with a 22% reduction in women and 13% in men and an average gain of 164 dementia-free days.

Scientists propose mechanisms linking latent varicella zoster virus reactivation to brain inflammation and amyloid/tau accumulation, and suggest vaccination may reduce neuroinflammation or boost immune “clearance” of harmful proteins; the Shingrix adjuvant is a leading suspect and similar signals have appeared for an RSV vaccine using the same adjuvant. Other modest population benefits - reduced heart attack and stroke - have been reported. Conflicting results exist: a large English hospital-record study found no Zostavax effect, so causation remains unproven and further research is required, even as many decide to vaccinate based on the current evidence.

Read on theguardian.com1 comments on Hacker News

Summary generated by AI from the linked article. hn.today is not affiliated with Hacker News or Y Combinator.

More in Other

The daily digest

Today's best Hacker News stories, summarized and screenshotted, one email a day.